(lp0
S'Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta ... Yahoo Finance - 15 hours ago NEW YORK, March 28, 2017  -- Scott+Scott, Attorneys at Law, LLP , a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta Therapeutics, Inc. ,&nbsp;...Looking at the Numbers for Sarepta Therapeutics, Inc.  - Baldwin Journal'
p1
aS"2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump Motley Fool - Mar 3, 2017 While Sarepta is well capitalized and will remain in growth mode, this company still has a long road ahead of it before it can hope to generate a profit.Vetr Advises Hold On Sarepta - BenzingaSarepta Therapeutics to Present Company Overview at the Cowen and Company 37th ... - Nasdaq"
p2
aS'Buy or Sell? What Analysts Recommends: CDW Corporation , Sarepta ... StockNewsJournal - 17 hours ago Sarepta Therapeutics, Inc. , at its latest closing price of $30.56, it has a price-to-book ratio of 4.87, compared to an industry average at 9.86.'
p3
aS"Sarepta Therapeutics Inc : Will Payors Reimburse Exondys 51? Smarter Analyst - Mar 10, 2017 Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc , as it appears that payors are still actively evaluating and reevaluating coverage of the company's muscular dystrophy drug Exondys 51.Payor Re-Evaluation On Exondys Positive For Sarepta - BenzingaSarepta  Exondys 51 Payor Discussions Progressing - Cowen - StreetInsider.com"
p4
aS'Stock in Review: Sarepta Therapeutics, Inc.  Rives Journal - 10 hours ago Sarepta Therapeutics, Inc.  currently has a Gross Margin  ratio of -0.426016. Robert Novy-Marx has provided investors with insights on finding high-quality value stocks.'
p5
aS'Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference Yahoo Finance - Mar 17, 2017 CAMBRIDGE, Mass., March 17, 2017  -- Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare&nbsp;...'
p6
aS"Sarepta  Q4 Loss Widens; Sales of Duchenne Drug Slow Yahoo Finance - Mar 1, 2017 Sarepta Therapeutics, Inc. SRPT reported wider-than-expected loss in the fourth quarter of 2016. Meanwhile, the biotech company's 2017 sales outlook fell largely short of expectations as the commercial launch of its only approved drug, Exondys 51, has&nbsp;...Sarepta Therapeutics Inc  Stock Heads Higher on Analyst Upgrade - Investorplace.comSarepta Therapeutics, Inc. | $SRPT Stock | Shares Fall On Poor Fourth Quarter ... - TickerTV News "
p7
aS'Sarepta Therapeutics, Inc. : Some of the key technical areas USA Commerce Daily - 15 hours ago With all other things going on, Sarepta Therapeutics, Inc.  has been on a run - rising 8.52 percent in just three months.'
p8
aS'Sarepta -2% after Q4 results Seeking Alpha - Feb 28, 2017 Q4 non-GAAP net loss of $38.7M or $0.71 per share vs. loss of $58.3M and $1.30 one year ago. Revenue of $5.4M recognized for EXONDYS 51 in Q4.'
p9
aS'Is a Surprise Coming for Sarepta Therapeutics  This Earnings Season? Yahoo Finance - Feb 27, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics, Inc. SRPT may be one such company.'
p10
a.